ECG Algorithm for Torsades de Pointes Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the risk of drug-induced torsades de pointes are inadequate, relying heavily on QTc interval prolongation, which is not specific or predictive, leading to overestimation or underestimation of torsadogenic risk, and there is a need for a more reliable diagnostic test to assess individual risk.
Innovation Solution
A computer-implemented method using electrocardiogram measurements to calculate ΔQTc, ΔTAmp, and ΔTpTe, combined through an algorithm to generate a principal component (PC1) that quantitatively assesses the risk of IKr channel inhibition and torsade de pointes, allowing for precise monitoring of patients and evaluation of drug torsadogenic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If QTc interval prolongation is used as the primary marker for assessing torsadogenic risk, then the assessment process is simple and widely applicable, but the measurement precision and reliability of torsadogenic risk prediction deteriorates due to lack of specificity
Solution Approach 1:
The patent segments the QT interval analysis into multiple independent components: QTc interval, T wave amplitude (TAmp), and TpTe interval. Each component is measured and analyzed separately to provide a comprehensive assessment of IKr channel inhibition, thereby improving prediction accuracy while maintaining operational feasibility through standardized measurement protocols.
Solution Approach 2:
The patent transitions from univariate QTc analysis to multivariate analysis by incorporating additional ECG dimensions (TAmp and TpTe). This dimensional expansion allows for more precise characterization of repolarization abnormalities and improves the specificity of torsadogenic risk prediction beyond what QTc alone can provide.
2Ease of manufacture
If QTc prolongation greater than 20 ms is used as the threshold for significant risk, then drug safety assessment is straightforward, but the reliability deteriorates due to overestimation of risk for some drugs and underestimation for others
Solution Approach 1:
The patent changes the assessment parameters from a single QTc threshold to a composite evaluation incorporating QTc, TAmp, and TpTe with their respective variations (ΔQTc, ΔTAmp, ΔTpTe). This parameter transformation enables more reliable differentiation between drugs with true torsadogenic potential and those with benign QT effects, reducing both false positives and false negatives.
3Measurement precision
If additional ECG parameters (TAmp, TpTe) and algorithmic analysis are incorporated to improve risk assessment accuracy, then measurement precision and reliability improve, but the device complexity and computational requirements increase
Solution Approach 1:
The patent develops a universal algorithmic framework that processes multiple ECG parameters (QTc, TAmp, TpTe) through a unified computational model. This multi-functional approach allows the same system to perform comprehensive torsadogenic risk assessment across different drug types and patient populations, improving reliability without proportionally increasing complexity through standardized processing protocols.
4Reliability
If comprehensive ECG analysis with multiple parameters is performed, then the reliability of individual patient risk assessment improves, but the loss of time for monitoring and evaluation increases
Solution Approach 1:
The patent implements preliminary action by establishing baseline ECG measurements (QTc, TAmp, TpTe) before drug administration and using predetermined algorithmic thresholds for risk classification. This preparatory approach allows for rapid interpretation of post-administration changes, reducing the time required for comprehensive risk assessment while maintaining high reliability through pre-established evaluation criteria.
Data Source
Figure 1A~1C
Figure 2A~2C
AI summary
The present invention relates to the field of cardiology and, more specifically, to a novel algorithm that can be used, in particular, in a method for determining if a drug is likely to induce a cardiac ventricular repolarisation disturbance, based on variations in electrocardiogram data.